CX-5461, RNA Polymerase I inhibitor

Catalog No. size PriceQuantity
M66052-2D 1 mM in DMSO (1.95 mL) $79
M66052-2S 2 mg solid $149
M66052-10S 10 mg solid $589


Product Information
Molecular Weight: 513.61
Formula: C27H27N7O2S
Purity: ≥98%
CAS#: 1138549-36-6
Solubility: DMSO up to 2 mM
Chemical Name: 2-(4-methyl-1,4-diazepan-1-yl)-N-((5-methylpyrazin-2-yl)methyl)-5-oxo-5H-benzo[4,5]thiazolo[3,2-a][1,8]naphthyridine-6-carboxamide
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.


Biological Activity: 

CX-5461 is the first potent, selective, and orally bioavailable inhibitor of RNA Polymerase I with an IC50 ~0.11 µM.  It showed good in vivo activities in tumor models. It selectively blocks RNA PolI transcription, PIC assembly and SL1-rDNA interaction. CX-5461 showed potent anti-proliferation activity in cancer cells and antitumor activity in A375 and MiaPaca xenografts. In a recent Cancer Cell paper, CX5461 was shown to induce p53-dependent apoptotic cell death of Em-Myc lymphoma cells via activation of the Rp-MDM2-p53 nucleolar surveillance pathway; selectively induced p53-mediated cell death of lymphoma cells in vivo while sparing normal B cells.  

How to Use: 

  • In vitro:  CX-5461 was used at 100-500 nM in vitro and in cell culture.
  • In vivo: In pancreatic carcinoma (MIA PaCa-2) and melanoma (A375) xenograft model, CX-5461 was administered orally at 50 mg/kg either once daily or every 3 days. In MV4;11 xenograft model, CX-5461 was administered intraperitoneally once a week at 125 mg/kg for the length of 25 days, or IP dosed at 25 mg/kg once a day on a 5-on, 2-off schedule over a period of 21 days. 


  • 1. Drygin D, et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. (2011) Cancer Res. 71(4):1418-30.
  • 2. Haddach M, et al. Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics. (2012) ACS Med. Chem. Lett., 3 (7), pp 602–606.
  • 3. Bywater MJ, et al Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53. (2012) Cancer Cell, 22(1), 51 – 65.

Products are for research use only. Not for human use.

Payment & Security

American Express Apple Pay Diners Club Discover Elo Google Pay JCB Mastercard PayPal Shop Pay Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed